Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Long-acting injectable cabotegravir is a novel integrase inhibitor currently in advanced clinical development for HIV prevention and treatment. We aimed to assess the terminal phase pharmacokinetics and safety of long-acting injectable cabotegravir in participants included in the HPTN 077 trial.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet HIV

Title: The lancet. HIV

Publisher: Elsevier BV

ISSN (Electronic): 2352-3018

ISSN (Print): 2352-3018

Publication date (Electronic): July 2020

Volume: 7

Issue: 7

Affiliations

[1 ] UCLA Center for Clinical AIDS Research and Education, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: rlandovitz@mednet.ucla.edu.

[2 ] Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

[3 ] University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

[4 ] Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.

[5 ] Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa.

[6 ] Bridge HIV, Population Health Division, San Francisco Department of Health, San Francisco, CA, USA.

[7 ] Department of Epidemiology, Milken Institute School of Public Health at The George Washington University, Washington, DC, USA.

[8 ] University of North Carolina Project-Malawi, Lilongwe, Malawi.

[9 ] Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa.

[10 ] School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

[11 ] UCLA Center for Clinical AIDS Research and Education, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

[12 ] Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.

[13 ] ViiV Healthcare, Durham, NC, USA.

[14 ] FHI 360, Washington, DC, USA.

Article

Publisher Item ID: S2352-3018(20)30106-5 Mid ID: NIHMS1658344

DOI: 10.1016/S2352-3018(20)30106-5

PMC ID: 7859863

PubMed ID: 32497491

SO-VID: 8ebf6f93-da11-447e-bd0c-a4a6347e6448

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 47

See all cited by